CD274 and ovarian carcinoma: Treatments targeting PD1 or PD-L1 have shown breakthrough curative antitumor effects in various types of cancer, including ovarian carcinoma, although only a limited number of patients appear to benefit from the immune checkpoint blockage method [31].